FDA Approves New Leqembi Subcutaneous Dosing Regimen for Alzheimer's
BIIB sits 73% above its 52-week low of $121.05.
Summary
The FDA approved a new starting dosage regimen for the subcutaneous formulation of Leqembi, Biogen's Alzheimer's drug, enabling at-home administration of the starter dose. This regulatory win simplifies administration and could broaden patient access, directly boosting the drug's commercial potential. It follows a series of mixed pipeline updates, including the recent advancement of Diranersen into late-stage trials and the Apellis acquisition. The approval strengthens Biogen's Alzheimer's franchise at a critical time, with the company facing a lowered profit forecast and upcoming R&D expenses. Next catalyst: Q2 earnings will reveal initial uptake and any updated guidance.
At the time of this announcement, BIIB was trading at $209.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31B. The 52-week trading range was $121.05 to $219.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.